ARP-100 produced concentration-dependent changes in flow-driven HUVEC networks. At 10 μM, vessels became narrower while retaining perfusability; 20 μM yielded nonperfusable networks, and 50 μM disrupted network formation. These findings apply to the tested fibrin-based vascular model. [2]
ARP100 reduces GPC4 shedding in diaphragm endothelial cells
Cell-based study · Immortalized mouse diaphragm endothelial cells (dECs) [1]
ARP100 reduced shed GPC4 detected in conditioned medium relative to control. This is a cellular substrate-shedding result, not an enzyme IC50 determination.
Literature-Reported Treatment Conditions
- Treatment concentration
- 60 nM
- Exposure duration
- 6 h
- Method
- Treatment in serum-free DMEM following 6 h starvation; conditioned-medium Western blot
- Reported limits
- ARP100 solvent and solvent fraction in the Figure 4D control are not specified in the read methods. Exact effect size and explicit replicate definition are not adopted.
Methods and source locations
Compound reported in the paper: ARP-100; Compound label in the paper: ARP100
Reported compound and model only; no salt conversion, exclusive supplier attribution or validation of the current Adooq lot.
Figure 4D image/caption; Results: MMP2 specifically cleaves Glypican4; Reagents, Cell lines, conditioned-media and Western blot methods
GPC4 in conditioned medium: Western blot with N-terminal GPC4 antibody. Figure 4 caption: mean ± SEM, Student’s t-test. — Figure 4D image/caption; Results: MMP2 specifically cleaves Glypican4; Reagents, Cell lines, conditioned-media and Western blot methods
Concentration-dependent remodeling of flow-driven HUVEC networks
Cell-based study · GFP-labeled HUVEC monocultures in fibrin within a single-channel microfluidic device; interstitial flow driven by a 10 mm H2O pressure difference [2]
ARP-100 altered vascular morphology and perfusability. At 10 μM vessels were narrower but remained perfusable; 20 μM produced nonperfusable narrow networks, and 50 μM prevented connected network formation. These high micromolar responses do not establish exclusive MMP-2 dependence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10, 20 or 50 μM
- Exposure duration
- Throughout network formation; day-5 failure described for 50 μM
- Method
- Added to culture medium under interstitial flow
- Vehicle
- DMSO control; final fraction not specified
- Reported limits
- No exact common imaging day is assigned to all Figure 5 panels; general culture duration is 5–7 days. Exclusive target selectivity at these concentrations was not demonstrated.
Methods and source locations
Compound reported in the paper: ARP-100; Compound label in the paper: ARP-100
Reported compound and model only; no salt conversion, exclusive supplier attribution or validation of the current Adooq lot.
Results 2.4–2.5; Figures 4e and 5a–e images/captions; Methods: cell culture, network formation, inhibitor treatment, perfusion/imaging and Statistics
Morphology and perfusability at 10 μM: Confocal GFP/40 kDa Texas Red dextran imaging. Perfusability = projected dextran-positive area / GFP-positive vessel area. Control n=5 devices; inhibitor groups n=3 devices; mean ± SD; t-tests. — Results 2.5; Figure 5a–e; perfusion/imaging methods; Statistics
Vascular network formation at 20 μM: GFP/dextran confocal imaging versus DMSO control; no decimal effect sizes inferred. — Results 2.4; Figure 4e; Figure 5a–e
Vascular network formation at 50 μM: GFP/dextran confocal imaging versus DMSO control. — Results 2.4; Figure 4e; Figure 5a